Ambit Biosciences Corp Reaches New 12-Month High at $21.44 (AMBI)
Ambit Biosciences Corp (NASDAQ:AMBI) set a new 52-week high on Friday, AnalystRatings.Net reports. The company traded as high as $21.44 and last traded at $17.12, with a volume of 105,198 shares. The stock had previously closed at $15.23.
Separately, analysts at BMO Capital Markets reiterated an “outperform” rating on shares of Ambit Biosciences Corp (NASDAQ:AMBI) in a research note to investors on Wednesday, August 14th. They now have a $23.00 price target on the stock, up previously from $10.00.
Ambit Biosciences Corp has a 52 week low of $6.219 and a 52 week high of $17.11. The stock has a 50-day moving average of $14.19 and a 200-day moving average of $11.38. The company’s market cap is $306.1 million.
Ambit Biosciences Corporation is a biopharmaceutical company. The Company focused on the discovery, development and commercialization of drugs to treat unmet medical needs in oncology, autoimmune and inflammatory diseases by inhibiting kinases that are important drivers for those diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.